HB Wealth Management
GANX icon

HB Wealth Management’s Gain Therapeutics GANX Stock Holding History

HB Wealth Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.1K Hold
12,783
– – ﹤0.01% 1862
2026
Q2 		$25.9K Buy
+12,783
New +$23.6K ﹤0.01% 1693

Other funds holding GANX

Apollon Wealth Management
Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return
Oliver Luxxe Assets
Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Benedict Financial Advisors
Benedict Financial Advisors Atlanta, Georgia $504M AUM 20.67% 1-Year Est. Return

HB Wealth Management's GANX Position: Q3 2026 in Review

HB Wealth Management held its Gain Therapeutics (GANX) position steady in Q3 2026 at 12,783 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

HB Wealth Management first reported a position in GANX in Q2 2026 and has held it in 2 quarters since. The position peaked at $25.9K in Q2 2026. 5 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

  • HB Wealth Management held 12,783 shares of Gain Therapeutics worth $22.1K as of Q3 2026.
  • HB Wealth Management left its Gain Therapeutics share count unchanged in Q3 2026.
  • Gain Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q3 2026, its #1862 holding.
  • HB Wealth Management first reported a position in Gain Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • HB Wealth Management's Gain Therapeutics position peaked at $25.9K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on HB Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.